Perspective – The case for zero bleeds and drug bioequivalence in the treatment of congenital hemophilia A in 2021 - Di Minno, Alessandro; Spadarella, Gaia; Esposito, Salvatore; Mathew, Prasad; Di Minno, Giovanni; Mannucci, Pier Mannuccio (Blood reviews, 2021)
Keywords: Bioequivalence; Cross-Over Studies; Emicizumab; Extended half-life FVIII products; Factor VIII - pharmacokinetics; HA and B; Half-Life; Hemophilia A - drug therapy; Hemorrhage - drug therapy; Hemorrhage - etiology; Hemostatics; Humans; Monogenic disorder; Newer determinants of FVIII half-life; Pharmaceutical Preparations; Phenotypic heterogeneity of patients; Standard half-life FVIII products; Tailored prophylaxis; Therapeutic Equivalency; von Willebrand Factor - metabolism; Zero bleeding; Zero bleeding; Emicizumab; Phenotypic heterogeneity of patients; Bioequivalence; Monogenic disorder; Newer determinants of FVIII half-life; Standard half-life FVIII products; HA and B; Extended half-life FVIII products; Tailored prophylaxis